Tissue Regenix Group announced that Steve Couldwell, its Chief Executive Officer, will be taking a temporary leave of absence from January 2019, predicted to last for first quarter, due to physical ill health in order to undergo medical treatment. The Board has approved interim management changes during the period to ensure effective operational performance and continuity of the Group's strategy. Chairman, John Samuel, will become Executive Chairman and Gareth Jones, currently CFO, will become Chief Operating Officer, both on an interim basis.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
61.9 GBX | +0.65% | +0.65% | +19.04% |
Mar. 19 | Tissue Regenix annual loss narrows sharply as revenue jumps | AN |
Mar. 19 | Earnings Flash (TRX.L) TISSUE REGENIX GROUP Reports FY23 Revenue $29.5M | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.04% | 54.36M | |
+5.89% | 32.95B | |
+18.09% | 7.82B | |
+31.25% | 4.17B | |
-28.10% | 2.72B | |
-18.15% | 1.41B | |
-33.33% | 1.15B | |
+9.61% | 980M | |
-37.56% | 873M | |
-26.41% | 831M |
- Stock Market
- Equities
- TRX Stock
- News Tissue Regenix Group plc
- Tissue Regenix Group plc Announces Interim Management Changes